Insititute for Clinical Pharmacodynamics: Publications

BY AUTHOR

Okusanya OO, Bhavnani SM, Hammel J, Minic P, Dupont LJ, Forrest A, Mulder GJ, Mackinson C, Ambrose PG, Gupta R.
Pharmacokinetic and pharmacodynamic evaluation of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infection. Antimicrob Agents Chemother 2009 Sep; 53(9):3847-54.

Rubino CM, Bhavnani SM, Ambrose PG, Forrest A, Loutit JS.
Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults. Pulm Pharmacol Ther 2009 Aug; 22(4):279-85.

Van Wart SA, Andes DR, Ambrose PG, Bhavnani SM.
Pharmacokinetic-pharmacodynamic modeling to support doripenem dose regimen optimization for critically ill patients. Diagn Microbiol Infect Dis 2009 Apr; 63(4):409-14.

Ambrose PG, Meagher AK, Passarell JA, Van Wart SA, Cirincione BB, Bhavnani SM, Ellis-Grosse EJ.
Application of patient population-derived pharmacokinetic-pharmacodynamic relationships to tigecycline breakpoint determination for staphylococci and streptococci. Diagn Microbiol Infect Dis 2009 Feb; 63(2):155-9.

Baddley JW, Patel M, Bhavnani SM, Moser SA, Andes DR
Association of fluconazole pharmacodynamics with mortality in patients with candidemia. Antimicrob Agents Chemother 2008 Sep; 52(9):3022-8.

Bradley JS, Sauberan JB, Ambrose PG, Bhavnani SM, Rasmussen MR, Capparelli EV.
Meropenem pharmacokinetics, pharmacodynamics, and Monte Carlo simulation in the neonate. Pediatr Infect Dis J 2008 Sep; 27(9):794-9.

Bhavnani SM, Forrest A, Hammel JP, Drusano GL, Rubino CM, Ambrose PG.
Pharmacokinetics-pharmacodynamics of quinolones against Streptococcus pneumoniae in patients with community-acquired pneumonia. Diagn Microbiol Infect Dis 2008 Sep; 62(1):99-101.

Ambrose PG, Anon JB, Bhavnani SM, Okusanya OO, Jones RN, Paglia MR, Kahn J, Drusano GL.
Use of pharmacodynamic endpoints for the evaluation of levofloxacin for the treatment of acute maxillary sinusitis. Diagn Microbiol Infect Dis. 2008 May;61(1):21-2.

Bhavnani SM, Ambrose PG.
Cost-effectiveness of oral gemifloxacin versus intravenous ceftriaxone followed by oral cefuroxime with/without a macrolide for the treatment of hospitalized patients with community-acquired pneumonia. Diagn Microbiol Infect Dis 2008 Jan; 60(1):59-64.

Ambrose PG, Forrest A, Craig WA, Rubino CM, Bhavnani SM, Drusano GL, Heine HS.
Pharmacokinetics-pharmacodynamics of gatifloxacin in a lethal murine Bacillus anthracis inhalation infection model. Antimicrob Agents Chemother. 2007 Dec;51(12):4351-5. Epub 2007 Sep 17.

Rubino CM, Ma L, Bhavnani SM, Korth-Bradley J, Speth J, Ellis-Grosse E, Rodvold KR, Ambrose PG, Drusano GL.
Evaluation of tigecycline penetration into colon wall tissue and epithelial lining fluid using a population pharmacokinetic model and Monte Carlo simulation. Antimicrob Agents Chemother. 2007 Nov;51(11):4085-9. Epub 2007 Sep 10.

Drusano GL, Ambrose PG, Bhavnani SM, Bertino JS, Nafziger AN, Louie A.
Back to the future: using aminoglycosides again and how to dose them optimally. Clin Infect Dis. 2007 Sep 15;45(6):753-60. Epub 2007 Aug 8.

Gumbo T, Louie A, Liu W, Brown D, Ambrose PG, Bhavnani SM, Drusano GL.
Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations. Antimicrob Agents Chemother. 2007 Jul;51(7):2329-36. Epub 2007 Apr 16.

Sader HS, Bhavnani SM, Ambrose PG, Jones RN, Pfaller MA.
Re-evaluation of the role of broad-spectrum cephalosporins against staphylococci by applying contemporary in vitro results and pharmacokinetic-pharmacodynamic principles. J Chemother. 2007 Feb;19(1):38-43.

Gumbo T, Louie A, Liu W, Ambrose PG, Bhavnani SM, Brown D, Drusano GL
Isoniazid's Bactericidal Activity Ceases because of the Emergence of Resistance, Not Depletion of Mycobacterium tuberculosis in the Log Phase of Growth. J Infect Dis. 2007 V195:194-201.

Bhavnani SM.
A call to arms. Nature Reviews Drug Discovery. 2007, V6:12.

Ambrose PG, Bhavnani SM, Rubino CM, Louie A, Gumbo T, Forrest A, Drusano GL.
Pharmacokinetics-pharmacodynamics of antimicrobial therapy: It's not just for mice anymore. 2007 Jan 1;44(1):79-86.

Smith PF, Tsuji B, Booker BM, Forrest A, Bajic S, Kelchlin P, Bhavnani SM, Jones RN, Ambrose PG.
Pharmacodynamics of cefprozil against Haemophilus influenzae in an in vitro pharmacodynamic model. Diagn Microbiol Infect Dis. 2006 Dec;56(4):379-86.

Smith J, Safdar N, Knasinski V, Simmons W, Bhavnani SM, Ambrose PG, Andes D.
Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother. 2006 Apr;50(4):1570-2.

Bhavnani SM, Passarell JA, Owen JS, Loutit JS, Porter SB, Ambrose PG.
Pharmacokinetic-pharmacodynamic relationships describing the efficacy of oritavancin in patients with Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2006 Mar;50(3):994-1000.

Bhavnani SM, Ambrose PG, Craig WA, Dudley MN, Jones RN.
Outcomes evaluation of patients with ESBL- and non-ESBL-producing Escherichia coli and Klebsiella species as defined by CLSI reference methods: report from the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis. 2006 Mar;54(3):231-6.

Hammel JP, Bhavnani SM, Jones RN, Forrest A, Ambrose PG.
Comparison of censored regression and standard regression analyses for modeling relationships between antimicrobial susceptibility and patient- and institution-specific variables. Antimicrob Agents Chemother. 2006 Jan;50(1):62-7.

Bhavnani SM, Hammel JP, Cirincione BB, Wikler MA, Ambrose PG.
Use of pharmacokinetic-pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem. Antimicrob Agents Chemother. 2005 Sep;49(9):3944-7.

Bhavnani SM, Hammel JP, Cirincione BB, Wikler MA, Ambrose PG.
Use of pharmacokinetic-pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem. Antimicrob Agents Chemother. 2005 Sep;49(9):3944-7.

Booker BM, Smith PF, Forrest A, Bullock J, Kelchlin P, Bhavnani SM, Jones RN, Ambrose PG.
Application of an in vitro infection model and simulation for reevaluation of fluoroquinolone breakpoints for Salmonella enterica serotype typhi. Antimicrob Agents Chemother. 2005 May;49(5):1775-81.

Bhavnani SM, Andes DR.
Gemifloxacin for the treatment of respiratory tract infections: in vitro susceptibility, pharmacokinetics and pharmacodynamics, clinical efficacy, and safety. Pharmacotherapy. 2005 May;25(5):717-40.

Fetterly GJ, Ong CM, Bhavnani SM, Loutit JS, Porter SB, Morello LG, Ambrose PG, Nicolau DP.
Pharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200-milligram dose for 3 days or a single 800-milligram dose. Antimicrob Agents Chemother. 2005 Jan;49(1):148-52.

Fetterly GJ, Ong C, Bhavnani SM, Loutit J, Porter S, Ambrose PG, Nicolau DP.
Characterization of oritavancin (ORI) pharmacokinetics (PK) in plasma and blister fluid in normal healthy volunteers. Antimicrobial Agents and Chemotherapy, 2005; 49: 148-152.

Bhavnani SM, Hammel JP, Jones RN, Ambrose PG.
Relationship between increased levofloxacin use and decreased susceptibility of Streptococcus pneumoniae in the United States. Diagn Microbiol Infect Dis. 2005 Jan;51(1):31-7.

Owens RC Jr, Bhavnani SM, Ambrose PG.
Assessment of pharmacokinetic-pharmacodynamic target attainment of gemifloxacin against Streptococcus pneumoniae. Diagn Microbiol Infect Dis. 2005 Jan;51(1):45-9.

Craig WA, Bhavnani SM, Ambrose PG.
The inoculum effect: fact or artifact? Diagn Microbiol Infect Dis. 2004 Dec;50(4):229-30.

Bhavnani SM, Owen JS, Loutit JS, Porter SB, Ambrose PG.
Pharmacokinetics, safety, and tolerability of ascending single intravenous doses of oritavancin administered to healthy human subjects. Diagnostic Microbiology and Infectious Disease Diagn Microbiol Infect Dis. 2004 Oct;50(2):95-102.

Ambrose PG, Anon JB, Owen JS, Van Wart S, McPhee ME, Bhavnani SM, Piedmonte M, Jones RN.
Use of pharmacodynamic end points in the evaluation of gatifloxacin for the treatment of acute maxillary sinusitis. Clin Infect Dis. 2004 Jun 1;38(11):1513-20.

Bhavnani SM, Callen WA, Forrest A, Gilliland KK, Collins DA, Paladino JA, Schentag JJ.
Effect of fluoroquinolone expenditures on susceptibility of Pseudomonas aeruginosa to ciprofloxacin in U.S. hospitals. Am J Health Syst Pharm. 2003 Oct 1;60(19):1962-70.

Ambrose PG, Bhavnani SM, Owens RC Jr.
Clinical pharmacodynamics of quinolones. Infect Dis Clin North Am. 2003 Sep;17(3):529-43.

Ambrose PG, Bhavnani SM, Cirincione BB, Piedmonte M, Grasela TH.
Gatifloxacin and the elderly: pharmacokinetic-pharmacodynamic rationale for a potential age-related dose reduction. J Antimicrob Chemother. 2003 Sep;52(3):435-40.

Bhavnani SM, Hammel JP, Forrest A, Jones RN, Ambrose PG.
Relationships between patient- and institution-specific variables and decreased antimicrobial susceptibility of Gram-negative pathogens. Clin Infect Dis. 2003 Aug 1;37(3):344-50.

Ambrose PG, Bhavnani SM, Jones RN.
Pharmacokinetics-pharmacodynamics of cefepime and piperacillin-tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases: report from the ARREST program. Antimicrob Agents Chemother. 2003 May;47(5):1643-6.

Jones RN, Rubino CM, Bhavnani SM, Ambrose PG.
Worldwide antimicrobial susceptibility patterns and pharmacodynamic comparisons of gatifloxacin and levofloxacin against Streptococcus pneumoniae . Antimicrob Agents Chemother. 2003 Jan;47(1):292-6.

Bhavnani SM, Ambrose PG, Jones RN.
Pharmacodynamics in the evaluation of drug regimens. Ann Pharmacother. 2002 Mar;36(3):530-2.

Bhavnani SM.
Benchmarking in health-system pharmacy: current research and practical applications. Am J Health Syst Pharm. 2000 Oct 15;57 Suppl 2:S13-20.

Moise PA, Forrest A, Bhavnani SM, Birmingham MC, Schentag JJ.
Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus. Am J Health Syst Pharm. 2000 Oct 15;57 Suppl 2:S4-9.

Bhavnani SM, Ballow CH.
New agents for Gram-positive bacteria. Curr Opin Microbiol. 2000 Oct;3(5):528-34.

Bhavnani SM, Drake JA, Forrest A, Deinhart JA, Jones RN, Biedenbach DJ, Ballow CH.
A nationwide, multicenter, case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia. Diagn Microbiol Infect Dis. 2000 Mar;36(3):145-58.